Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and
orthopedics company, today announced the appointment of Patrick
Fisher as President of the Orthofix Global Orthopedics business. In
this role, Fisher will serve on the company’s Executive Leadership
team, reporting to Orthofix President and CEO Massimo
Calafiore.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240815706187/en/
Patrick Fisher, President of Orthofix
Global Orthopedics (Photo: Business Wire)
Fisher joins Orthofix from Stryker Corporation, a global medical
technology company where he served as the Vice President and
General Manager of the Foot and Ankle business unit. Prior to
Stryker, Fisher served as the President of Lower Extremity and
Biologics for Wright Medical, which was acquired by Stryker in
2020. After joining Wright Medical in 2002, he served in multiple
roles of increasing responsibility including Vice President of U.S.
Sales.
“Patrick has led global teams in the successful development and
execution of innovative strategies focused on driving commercial
optimization across sales, marketing, R&D, clinical research
and medical education,” said Calafiore. “We are excited to welcome
him to our team, and I am confident his leadership, experience and
broad familiarity with the Orthopedics market will help us further
grow this franchise and expand our market presence.”
“Orthofix has a uniquely differentiated orthopedics portfolio
with a history of clinical innovation that goes back to its early
beginnings in 1980,” said Fisher. “I have long been aware of the
great products and work done by the Orthofix orthopedics team, and
I am honored to have the opportunity to lead this area of the
organization. I look forward to working with the team to help drive
growth and accelerate this important area of the business.”
Fisher has a Bachelor of Arts in International Studies from
Rhodes College and a Master of Business Administration in
International Business from the University of Memphis.
Additionally, he is a board member of the Greater Memphis Medical
Device Council, the Memphis Chairman’s Circle and the University of
Tennessee Research Advisory Board.
As an inducement to enter into employment with Orthofix, Fisher
was granted (i) performance-based vesting restricted stock units
that settle into 30,637 shares of common stock at target
achievement, (ii) time-based vesting restricted stock units that
settle into 15,319 shares of common stock, and (iii) stock options
to purchase 35,195 shares of common stock. The performance-based
vesting restricted stock units vest at the end of a three-year
performance period based on the Company’s total stockholder return
relative to an industry peer group index during such period, while
the time-based vesting restricted stock units vest in equal
tranches over three years. The stock options vest upon achievement
of both service- and performance-based criteria, whichever is the
later of (a) the date certain service-based conditions are met
(which will be met over three years) and (b) the date that the
average closing price of the Company’s common stock over a
one-month calendar period has been equal to or great than 150% of
the closing price of the Company’s common stock on the grant date.
The grants, which were approved by Orthofix’s Board of Directors,
were made under standalone inducement award agreements approved
pursuant to NASDAQ Marketplace Rule 5635(c)(4).
About Orthofix
Orthofix is a leading global spine and orthopedics company with
a comprehensive portfolio of biologics, innovative spinal hardware,
bone growth therapies, specialized orthopedic solutions, and a
leading surgical navigation system. Its products are distributed in
more than 60 countries worldwide.
The Company is headquartered in Lewisville, Texas, where it
conducts general business, product development, medical education
and manufacturing, and has primary offices in Carlsbad, CA, with a
focus on spine and biologics product innovation and surgeon
education, and Verona, Italy, with an emphasis on product
innovation, production, and medical education for orthopedics. The
combined Company’s global R&D, commercial and manufacturing
footprint also includes facilities and offices in Irvine, CA,
Toronto, Canada, Sunnyvale, CA, Maidenhead, UK, Munich, Germany,
Paris, France and São Paulo, Brazil.
Forward-Looking Statements
This news release may include forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934,
as amended, and Section 27A of the Securities Act of 1933, as
amended. In some cases, you can identify forward-looking statements
by terminology such as “may,” “will,” “should,” “expects,” “plans,”
“anticipates,” “believes,” “estimates,” “projects,” “intends,”
“predicts,” “potential,” “continue” or other comparable
terminology. Orthofix cautions you that statements included in this
news release that are not a description of historical facts are
forward-looking statements that are based on the Company’s current
expectations and assumptions. Each forward-looking statement
contained in this news release is subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statement. Applicable risks
and uncertainties include, among others: the ability of newly
launched products to perform as designed and intended and to meet
the needs of surgeons and patients, including as a result of the
lack of robust clinical validation; and the risks identified under
the heading “Risk Factors” in Orthofix Medical Inc.’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2023, which was
filed with the Securities and Exchange Commission (SEC) on March 5,
2024. The Company’s public filings with the SEC are available at
www.sec.gov. You are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date when
made. Orthofix does not intend to revise or update any
forward-looking statement set forth in this news release to reflect
events or circumstances arising after the date hereof, except as
may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240815706187/en/
Media Relations Denise Landry DeniseLandry@Orthofix.com
214.937.2529 Investor Relations Julie Dewey
JulieDewey@Orthofix.com 209.613.6945
Orthofix Medical (NASDAQ:OFIX)
過去 株価チャート
から 8 2024 まで 9 2024
Orthofix Medical (NASDAQ:OFIX)
過去 株価チャート
から 9 2023 まで 9 2024